Airborne sued for allegedly lying about nutritional value of its supplements | RB Health

You Were Sick. You Trusted the Label. You Got a Quarter of What You Paid For.

Picture the moment. You feel a cold coming on. Maybe it’s the back of your throat, or that familiar weight behind your eyes. You’re standing in a pharmacy or a big-box store, and you reach for Airborne because the name is everywhere, because the label is bold and confident, because it says right there on the front: Vitamin C 1,000 mg. You think: that’s a real dose. That’s something that might actually help.

You are not a biochemist. You are not a regulatory attorney. You are a person who reads labels because that is what labels are for. The dosage number is the whole point of buying a supplement. It is the one piece of information that tells you whether what you’re swallowing does anything meaningful. And the company that makes Airborne knows this. That number is, in the words of the lawsuit, “prominently and conspicuously displayed on each of the Products’ principal display panel to grab the consumer’s attention.”

They grabbed your attention. They grabbed your $18.49. And they gave you 250 milligrams of Vitamin C per tablet — one quarter of what the front label announced.

To get the 1,000 mg dose you thought you were taking, you’d have to chew four tablets. But the label didn’t tell you that. So you took one, maybe two, and went about your day thinking you’d given your immune system what it needed. The deception here is quiet and clinical. There is no explosion, no recall, no dramatic injury. There is just a number on a package that does not mean what any reasonable person would think it means, repeated across an entire product line, for as long as the company could keep getting away with it.

The people harmed here are not wealthy investors who lost a portfolio point. They are people buying supplements at retail drugstores for their families, making small, careful decisions about their health with the money they have. The lawsuit was filed on behalf of California consumers, but Airborne is sold nationally. The population of people who bought one of these products and got a fraction of the dose they expected is, at minimum, in the hundreds. The complaint says the class is likely far larger.

The damage is not just financial, though the financial deception is real. The damage is the erosion of the one thing a consumer has in a store aisle: the ability to read a label and trust it.

Legal Receipts: What the Complaint Actually Says

The following are verbatim passages from Case 2:26-cv-04765, filed May 2, 2026, in the United States District Court for the Central District of California.

“Defendant deceptively labels certain of its Airborne Products by misrepresenting the dosage amount of each chewable tablet, gummy, or effervescent tablet. Specifically, the front labels of the Airborne Products prominently advertise a certain dosage amount of Vitamin C, for example, ‘VITAMIN C 1,000 MG.’ Reasonable consumers are led to believe that each chewable tablet, gummy, or effervescent tablet contains the advertised dosage amount.”

• This passage establishes the core theory of liability: the design of the label, with a large dosage claim on the principal display panel, creates a false impression in a reasonable consumer’s mind about what a single unit delivers.
• The word “prominently” is legally significant. The complaint is arguing that this is not fine-print ambiguity. RB Health chose to put the number where your eyes go first.

“For example, consumers must ingest four chewable tablets of the Airborne Vitamin C 1,000 mg Very Berry Chewable Tablets Product to achieve the advertised 1,000 mg dosage of Vitamin C.”

• This is the most concrete factual allegation in the complaint. One product. One purchase. Four tablets required. The front label says 1,000 mg. Each tablet contains 250 mg. The gap is not a rounding error; it is a 75% shortfall per unit.
• The plaintiff paid approximately $18.49 for a bottle she believed delivered 1,000 mg per tablet. On a per-milligram basis, she was paying four times the implied price per unit of Vitamin C.

“Defendant charges consumers a premium for the Products, while cutting costs and reaping the financial benefits of selling dietary supplements with less than the advertised per-unit dosage.”

• This passage frames the conduct as a deliberate profit mechanism, not a labeling oversight. Less Vitamin C per unit means lower production cost per unit. The premium price stays the same. The margin widens.
• The complaint argues this was a choice RB Health made to compete in a crowded supplement market by appearing to offer high-dose products without actually producing them.

“The senior officers and directors of Defendant allowed the Products to be sold with full knowledge or reckless disregard that the challenged claims are fraudulent, unlawful, and misleading.”

• This allegation targets corporate leadership directly. It is the foundation for the punitive damages claim. “Reckless disregard” is not an accident; it is a legal standard for conscious indifference to known wrongdoing.
• The complaint is saying that whoever approved these labels at RB Health either knew what the labels implied was false, or chose not to find out.

“Defendant’s competitors correctly label and sell their Vitamin C supplements to accurately reflect the correct amount of Vitamin C contained in each chewable tablet, gummy, or effervescent tablet unit. They do so by specifying on the front label the amount of Vitamin C per chewable tablet, gummy, or effervescent tablet unit. Alternatively, Defendant’s competitors disclose on their products’ front labels that the advertised dosage amount does not apply per individual chewable tablet, gummy, or effervescent tablet, and instead applies ‘per serving.’ Defendant chose not to adopt either disclosure practice for the Airborne Products.”

• This passage is devastating for any “industry standard” defense RB Health might raise. The complaint documents that the rest of the industry already solved this problem. Two different compliant labeling approaches exist. Airborne used neither.
• “Defendant chose not to adopt either disclosure practice” is the most precise and damaging phrase in the entire complaint. It converts what might look like a regulatory gray area into a documented, affirmative business decision.

What You Were Told vs. What Was Actually in the Bottle

The gap between Airborne’s front-label claims and the documented reality is not a matter of interpretation. The complaint establishes specific, documented contrasts across multiple product lines.

• Claimed: “VITAMIN C 1,000 MG” displayed prominently on the front label of Airborne Vitamin C 1,000 mg Very Berry Chewable Tablets, with no per-serving qualifier visible to consumers. Reality: Each tablet contains 250 mg of Vitamin C. A consumer must take four tablets to reach the advertised dose.
• Claimed: Airborne Immune Support Gummies (750 mg Vitamin C) front label implies the featured dosage is what each gummy delivers. Reality: Two gummies are required to achieve the advertised dosage.
• Claimed: Airborne Vitamin C + Zinc Gummies, Airborne Elderberry + Zinc + Vitamin C Gummies, and Airborne Triple Action Immune Support Effervescent Tablets all display a headline dosage figure on the principal display panel. Reality: All three require two units per serving to reach the advertised amount.
• Claimed (implicitly): The label design was a reasonable and standard industry practice. Reality: Competing brands already disclosed per-unit versus per-serving amounts on front labels. RB Health’s own competitors had solved this problem. Airborne’s approach was a documented outlier.

The Business Logic of Selling Less and Charging More

The complaint does not frame this as accidental. It documents a competitive market dynamic in which RB Health made a calculated decision to appear to offer high-dose supplements without actually producing them.

• The global dietary supplements market was estimated at nearly USD $152 billion in 2021 and is projected to reach USD $300 billion by 2028. The complaint places Airborne’s conduct squarely in the context of a race for market share in an exploding industry.
• The complaint states: “Rather than creating the actual high-dosage dietary supplements that consumers desire, Defendant makes Products that deliver a lower dosage of Vitamin C per unit, and then markets the Products to consumers through deceptive labeling.” Lower production cost, premium price point. The margin difference between a tablet with 250 mg of Vitamin C and one with 1,000 mg is real money at scale.
• The Very Berry Chewable Tablets retailed for approximately $18.49 per package, purchased by Plaintiff Robinson in December 2025. Consumers paid for the implied value of 1,000 mg per tablet. The actual value delivered per unit was one quarter of that.
• The complaint alleges RB Health “sought an unfair advantage over its lawfully acting competitors” by using deceptive labels to win market share from brands that were playing by the rules. Companies that disclosed per-unit dosages accurately were competing at a structural disadvantage against a brand displaying a number four times larger on its front label.
• The lawsuit alleges RB Health’s senior officers and directors allowed this to continue with “full knowledge or reckless disregard” — language the complaint uses as the predicate for punitive damages, signaling that plaintiffs believe this was a knowing profit decision, not a compliance failure.

The Ambiguity Airborne Exploited: “Per Serving” vs. “Per Tablet”

The deception in this case did not require inventing a false number. It required exploiting the gap between what a dosage claim says and what a reasonable consumer understands it to mean, a gap that the rest of the supplement industry had already closed.

• Supplement labeling rules distinguish between the amount of an ingredient per serving and the amount per individual unit. A “serving” of Airborne’s chewable tablets may technically be defined as four tablets in the supplement facts panel. The complaint alleges that RB Health placed the serving-size dosage on the front label without any indication that the number applied to multiple units, not one.
• Competing brands resolved this ambiguity in one of two ways: either listing the per-unit dosage directly on the front label, or explicitly labeling the headline figure as “per serving.” The complaint documents that Airborne used neither approach. This was not a gap in regulatory language that went unnoticed; it was a disclosure practice that competitors had already adopted, and Airborne declined to follow.
• California’s Sherman Food, Drug, and Cosmetic Law, cited in the complaint under Cal. Health & Safety Code § 110390, prohibits labeling that is “false or misleading in any particular.” The complaint argues that placing a per-serving dosage figure in the primary display space without a per-serving qualifier crosses that line, even if the serving-size information technically exists elsewhere on the package.
• The California Unfair Competition Law adds a second layer: the “unfair” prong covers conduct that “offends public policy” and causes consumer injury that is “not outweighed by benefits to consumers or competition, and not one consumers themselves could reasonably have avoided.” The complaint argues that a consumer standing in a store aisle, reading a front label designed to grab attention, could not reasonably have been expected to do the math required to detect the discrepancy.

Inside the Label: What the Front Panel Shows vs. What’s Actually There

Who Gets Hurt: Mapping the Damage

Public Health

The deception here intersects directly with consumer health decision-making in a way that goes beyond financial loss.

• Consumers who purchased Airborne products for immune support believed they were taking a meaningful therapeutic dose. If each tablet delivers only 250 mg and the consumer takes one, they received one quarter of the dose they believed they were taking. Decisions about whether to take additional supplements, see a doctor, or rely on the product as part of a health regimen were made based on false information.
• The supplement market context matters. The complaint notes there has been a “significant increase in the prevalence of supplement use” over the past 20 years, with a global market projected to reach $300 billion by 2028. Millions of people are making health decisions based on supplement labels every day. A systemic labeling deception in this market affects health literacy at scale.
• The complaint does not allege physical injury, and this article does not assert one. The public health harm documented here is informational: consumers were denied the accurate data they needed to make informed decisions about their own supplementation.

Economic Inequality

The financial harm from this deception falls disproportionately on people who can least afford to overpay for products that don’t deliver what they promise.

• Plaintiff Yalinda Robinson paid approximately $18.49 for a bottle of Airborne at a retail store in Los Angeles County. That is a real expenditure for a working person buying a health product for personal and family use. She received one quarter of the per-tablet Vitamin C she expected to receive.
• Supplement purchases made by working-class consumers at drugstores and big-box retailers are budget-sensitive decisions. A consumer who knows each tablet contains 250 mg, not 1,000 mg, might buy a different product, a different brand, or a larger quantity to get the dose they want. Airborne’s labeling removed that choice.
• The class is defined as all California consumers who purchased the Products for personal and household use. These are ordinary retail consumers, the complaint’s language makes this explicit, making “personal, family, or household purposes” the defining characteristic of the class. This is not a sophisticated-investor case. It is a case about people standing in store aisles trusting labels.
• Because individual damages per purchase are small relative to the cost of individual litigation, the class action mechanism is, as the complaint states, “the only feasible mechanism that allows an opportunity for legal redress and justice” for most affected consumers. Without it, RB Health faces no meaningful accountability from any individual plaintiff.

This Is Exactly How It Was Designed to Work

The Airborne case is not a story of one bad actor getting caught. It is a working demonstration of how the structure of the consumer goods market makes deceptive labeling a rational business strategy.

• The dietary supplement industry operates under lighter regulatory oversight than pharmaceutical products. The complaint cites California’s Sherman Food, Drug, and Cosmetic Law and federal consumer protection frameworks, but the complaint itself is a private class action, not a government enforcement action. That means the burden of catching and punishing this conduct fell on one consumer who happened to notice, hire a lawyer, and file suit. RB Health’s compliance incentive structure depended on not being caught by exactly this kind of individual.
• The per-unit versus per-serving distinction is not a new regulatory puzzle. Competing brands had already developed two separate compliant labeling approaches. The complaint documents this explicitly. RB Health operated in an industry where the right answer was visible and available. It chose the more profitable wrong answer.
• The complaint estimates the class at “at least in the hundreds” of consumers, and the amount in controversy exceeds $5 million. But the remedy sought, restitution of the premium paid for mislabeled products, is limited by what can be proven at the individual transaction level. The broader market damage from years of inflated market share gained through deceptive labeling is not easily quantifiable and may never be fully compensated.
• Class actions for small-dollar consumer fraud are structurally difficult. Individual damages are too small to justify individual suits. Defendants can use the litigation process to outlast plaintiffs. The complaint specifically invokes equitable relief precisely because damages alone may not be adequate to compensate class members who purchased products more than three years before the filing date.
• The complaint’s allegation that senior officers and directors acted with “full knowledge or reckless disregard” of the fraudulent labeling points to the core systemic dynamic: when the expected cost of deception (litigation risk, potential settlement) is lower than the expected benefit (market share gained over competitors, premium pricing sustained), the rational corporate calculation is to continue until forced to stop.